|Summary sheet: MPT|
|Common names||MPT, Methylpropyltryptamine|
|Routes of Administration|
N-Methyl-N-propyltryptamine (abbreviated MPT; also known as Methylpropyltryptamine) is a synthetic psychedelic of the tryptamine class that has reported to display powerful hallucinogenic and sometimes entactogenic effects. It is structurally analogous to N,N-dimethyltryptamine (DMT) and various base psychedelic tryptamines by which one can have a "breakthrough" experience such as MET, EPT, and DPT.
While little is known aboout the pharmacology of this substance, early reports indicate that vaporizing or freebasing the compounds shares most of the core components of the DMT experience, just with its own stylistic pharmacodynamic and kinetic variations.
MPT is extremely uncommon and has little history of human usage. It has never been documented as being sold on the street and is instead primarily acquired through the use of research chemical vendors and outfits who specialize in the sale of exotic psychoactive chemicals.
MPT, or N-methyl-N-propyltryptamine, is a synthetic indole molecule of the tryptamine class. Tryptamines share a core structure that comprises a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. Unlike DMT, which contains two methyl groups, MPT contains groups of one methyl and one propyl carbon chains bound to the terminal amine RN of its tryptamine backbone.
n 2019, Chadeayne et al. published the crystal structure of MPT. The authors describe the structure as "...a single molecule in the asymmetric unit, with an indole group that demonstrates a mean deviation from planarity of 0.015 A°."
Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based on its structure and subjective effect similarities to other tryptamine psychedelics such as psilocin and DMT. With this in mind, MPT is thought to act as an 5-HT2A partial agonist.
However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- After images
- Brightness alteration
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational MPT use do not appear to have been studied in any scientific context and the exact toxic dose is unknown. This is because MPT is a research chemical with very little history of human use. Anecdotal evidence from people within the psychonaut community who have tried MPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one uses harm reduction practices when using this drug.
Tolerance and addiction potential
MPT is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of MPT is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). MPT presents cross-tolerance with all psychedelics, meaning that after the consumption of MPT all psychedelics will have a reduced effect.
Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be harmless in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
- Tramadol - Tramadol lowers seizure threshold and psychedelics may cause occasional seizures.
- Stimulants - Stimulants may provoke anxiety or thought loops.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- Germany: MPT is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
- New Zealand: MPT is an analogue of DMT, so is a Class C controlled substance in New Zealand.
- Switzerland: MPT is not controlled under Buchstabe A, B, C and D. It could be considered legal.
- United Kingdom: MPT is a Class A controlled substance in the United Kingdom as a result of the tryptamine catch-all clause.
- United States: MPT is unscheduled in the United States. It may be considered an analogue of DET, a Schedule I compound under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
This article does not cite enough references.
You can help by adding some.
- Chadeayne, A. R., Golen, J. A., Manke, D. R. (28 July 2019). "N -Methyl- N -propyltryptamine (MPT)". IUCrData. 4 (7): x190962. doi:10.1107/S2414314619009623. ISSN 2414-3146.
- Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. eISSN 1937-6995. ISSN 1556-9039. OCLC 163567183. PMC . PMID 19415589.
- "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
- "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Schedule 1 Class A controlled drugs". "Reprint as at 13 August 2019: Misuse of Drugs Act 1975". Parliamentary Counsel Office. Retrieved January 7, 2020.
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- "Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020.